As it concerns, Legchenko et al., in a SU5416/hypoxia-induced PAH rat model, demonstrated that the oral administration of pioglitazone (a PPARγ agonist) fully abolishes severe PAH and vascular remodeling, and prevents RVF (Figure 3). Here, PPARG is linked to pulmonary arterial hypertension.